

# Ismail Can

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7453479/publications.pdf>

Version: 2024-02-01

21  
papers

1,079  
citations

1040056

9  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1732  
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. <i>Cancer Cell</i> , 2017, 31, 270-285.	16.8	406
2	Human Thanatobiome Succession and Time Since Death. <i>Scientific Reports</i> , 2016, 6, 29598.	3.3	136
3	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3787.	12.8	112
4	p21 produces a bioactive secretome that places stressed cells under immunosurveillance. <i>Science</i> , 2021, 374, eabb3420.	12.6	112
5	Distinctive thanatobiome signatures found in the blood and internal organs of humans. <i>Journal of Microbiological Methods</i> , 2014, 106, 1-7.	1.6	108
6	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	1.4	53
7	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021, 29, 1529-1540.	8.2	43
8	The apoptotic thanatotranscriptome associated with the liver of cadavers. <i>Forensic Science, Medicine, and Pathology</i> , 2015, 11, 509-516.	1.4	25
9	In vivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	4.4	14
10	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	3.4	14
11	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. <i>Leukemia</i> , 2022, 36, 1635-1645.	7.2	12
12	A possible role for WNT5A hypermethylation in Pediatric Acute Lymphoblastic Leukemia. <i>Turkish Journal of Haematology</i> , 2015, 32, 127-135.	0.5	10
13	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. <i>Experimental Hematology</i> , 2022, 108, 1-7.	0.4	9
14	Novel interactions between erythroblast macrophage protein and cell migration. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 60, 24-27.	1.4	7
15	Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy. <i>Blood</i> , 2020, 136, 6-7.	1.4	6
16	Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1093-1103.	1.3	4
17	Xenotransplantation of human cryopreserved parathyroid tissue isolated from parathyroid adenomas to normocalcemic rabbits. <i>Turkish Journal of Surgery</i> , 2017, 33, 91-95.	0.5	4
18	Parathyroid allotransplantation in rabbits without cultivation. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 280-4.	1.3	2

#	ARTICLE	IF	CITATIONS
19	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 901-901.	1.4	1
20	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
21	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020, 136, 28-29.	1.4	0